R&D Spending Showdown: AstraZeneca PLC vs Sarepta Therapeutics, Inc.

AstraZeneca vs Sarepta: R&D Spending Strategies Unveiled

__timestampAstraZeneca PLCSarepta Therapeutics, Inc.
Wednesday, January 1, 2014557900000094231000
Thursday, January 1, 20155997000000146394000
Friday, January 1, 20165890000000188272000
Sunday, January 1, 20175757000000166707000
Monday, January 1, 20185932000000401843000
Tuesday, January 1, 20195958000000560909000
Wednesday, January 1, 20205991000000722343000
Friday, January 1, 20219736000000771182000
Saturday, January 1, 20229762000000877090000
Sunday, January 1, 202310935000000877387000
Monday, January 1, 202413583000000
Loading chart...

Unleashing insights

R&D Spending: A Tale of Two Innovators

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, AstraZeneca PLC and Sarepta Therapeutics, Inc. have shown contrasting approaches in their R&D investments. From 2014 to 2023, AstraZeneca's R&D expenses surged by nearly 96%, peaking at over $10 billion in 2023. This reflects their aggressive strategy to maintain a leading edge in drug development. In contrast, Sarepta Therapeutics, a smaller player, increased its R&D spending by approximately 830% during the same period, reaching close to $880 million in 2023. This remarkable growth underscores Sarepta's dedication to expanding its niche in genetic medicine. While AstraZeneca's vast resources allow for broad-spectrum research, Sarepta's focused investments highlight its strategic commitment to specialized therapies. This spending showdown offers a fascinating glimpse into the diverse strategies driving pharmaceutical innovation today.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025